0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Cassava Sciences Inc

Healthcare US SAVA

21.73USD
0.99(4.77%)

Last update at 2024-04-25T20:11:00Z

Day Range

20.4321.88
LowHigh

52 Week Range

12.3238.53
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -76.24600M -32.38500M -6.33400M -4.63100M -6.55700M
Minority interest - - - - -
Net income -72.47200M -31.80200M -5.85400M -4.24500M -6.55700M
Selling general administrative 11.99M 8.05M 3.74M 3.39M 3.69M
Selling and marketing expenses - - - - -
Gross profit -0.00180M - -0.34600M -1.56800M -2.96900M
Reconciled depreciation 1.30M 0.53M 0.02M 0.06M 0.07M
Ebit -81.32100M -33.40200M -6.44600M -5.01700M -6.73100M
Ebitda -80.02000M -32.86800M -7.13800M -4.95900M -6.66200M
Depreciation and amortization 1.30M 0.53M -0.69200M 0.06M 0.07M
Non operating income net other - 0.48M 0.11M 0.33M 0.10M
Operating income -80.02000M -32.86800M -6.44600M -4.95900M -6.66200M
Other operating expenses 80.02M 32.87M 6.79M 4.96M 6.66M
Interest expense -3.77400M 0.48M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 2.78M 0.05M 0.11M 0.33M 0.10M
Net interest income 2.78M 0.05M 0.11M 0.33M 0.10M
Extraordinary items - - - - -
Non recurring - - -0.34600M - -
Other items - - - - -
Income tax expense -3.77400M -0.58300M -0.48000M -0.38600M -0.10500M
Total revenue -0.00180M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 80.02M 32.87M 6.79M 4.96M 6.66M
Cost of revenue - - 0.35M 1.57M 2.97M
Total other income expense net 3.77M 0.48M 0.11M 0.33M 0.10M
Discontinued operations - - - - -
Net income from continuing ops -76.24600M -32.38500M -6.33400M -4.63100M -6.55700M
Net income applicable to common shares -76.24600M -32.38500M -6.33400M -4.63100M -6.55700M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 234.83M 266.78M 94.30M 23.49M 20.14M
Intangible assets 0.62M 1.07M - - -
Earning assets - - - - -
Other current assets 10.21M 11.04M 0.49M 0.27M 0.23M
Total liab 7.29M 12.87M 2.10M 1.39M 0.51M
Total stockholder equity 227.54M 253.91M 92.20M 22.10M 19.63M
Deferred long term liab - - - - -
Other current liab 2.94M 0.63M 0.09M 0.00900M 0.22M
Common stock 511.09M 461.22M 267.12M 190.69M 0.02M
Capital stock 0.04M 0.04M 0.04M 0.02M 0.02M
Retained earnings -283.55200M -207.30600M -174.92100M -168.58700M -163.95600M
Other liab 0.20M 0.19M - - -
Good will - - - - -
Other assets - 0.40M 0.29M - 0.01M
Cash 201.01M 233.44M 93.51M 23.08M 19.81M
Cash and equivalents - - - - -
Total current liabilities 7.06M 12.53M 1.86M 1.39M 0.51M
Current deferred revenue - 4.68M 0.80M 0.83M -
Net debt -200.87600M -233.20100M -93.21300M -22.99100M -19.80700M
Short term debt 0.10M 0.10M 0.06M 0.09M -
Short long term debt - - - - -
Short long term debt total 0.14M 0.24M 0.29M 0.09M -
Other stockholder equity 511.05M 461.18M 267.09M 191.56M 184.47M
Property plant equipment 22.99M 20.83M 0.31M 0.05M 0.09M
Total current assets 211.23M 244.48M 93.99M 23.35M 20.04M
Long term investments - - - - -
Net tangible assets 226.92M 252.84M 92.20M 22.10M 19.63M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.02M 7.13M 0.91M 0.45M 0.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.90000M -0.90000M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - -207.30600M -174.92100M -168.58700M -163.95600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.40M 0.29M 0.09M -0.00100M
Deferred long term asset charges - - - - -
Non current assets total 23.61M 22.30M 0.31M 0.14M 0.10M
Capital lease obligations 0.14M 0.24M 0.29M 0.09M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.71200M -22.21400M 0.36M -0.01800M 0.00000M
Change to liabilities -3.44900M 10.82M 0.46M 0.79M -0.62100M
Total cashflows from investing activities -2.71200M -22.21400M 0.36M -0.01800M -0.01800M
Net borrowings - - - - -
Total cash from financing activities 47.80M 192.34M 75.45M 5.81M 14.10M
Change to operating activities -1.18600M -6.31900M -0.17000M 0.60M -0.54000M
Net income -76.24600M -32.38500M -6.33400M -4.63100M -6.55700M
Change in cash -32.42200M 139.93M 70.42M 3.27M 9.33M
Begin period cash flow 233.44M 93.51M 23.08M 19.81M 10.48M
End period cash flow 201.01M 233.44M 93.51M 23.08M 19.81M
Total cash from operating activities -77.51400M -30.19600M -5.38200M -2.51400M -4.77000M
Issuance of capital stock 47.33M 190.52M 70.25M 0.00000M 14.10M
Depreciation 1.30M 0.53M 0.02M 0.06M 0.07M
Other cashflows from investing activities - - 0.36M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 192.34M 5.20M 5.81M 14.10M
Other cashflows from financing activities 0.47M 1.82M 5.20M 5.87M -0.06000M
Change to netincome 2.07M 1.76M 0.64M 1.30M 2.39M
Capital expenditures 2.71M 22.21M 0.35M 0.02M 0.02M
Change receivables - - - - -
Cash flows other operating - -10.92800M -0.22200M -0.02300M -0.04900M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 139.93M 70.42M 3.27M 9.33M
Change in working capital -4.63500M -0.10400M 0.29M 0.76M -0.67000M
Stock based compensation 2.07M 1.76M 0.99M 1.30M 2.39M
Other non cash items - -139.92300M -0.34600M -1.67000M -10.66800M
Free cash flow -80.22600M -52.41000M -5.38200M -2.53200M -4.77000M

Fundamentals

  • Previous Close 20.74
  • Market Cap1009.65M
  • Volume901028
  • P/E Ratio-
  • Dividend Yield0.34%
  • EBITDA-102.54200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -68.03200M
  • Diluted EPS TTM-2.29

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
SAVA
Cassava Sciences Inc		 0.99 4.77% 21.73 - 23.53 - 7.55 -10.0291
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences Inc

7801 North Capital of Texas Highway, Austin, TX, United States, 78731

Key Executives

Name Title Year Born
Mr. Remi Barbier Founder, Chairman, Pres & CEO 1960
Mr. Eric J. Schoen Chief Financial Officer 1968
Dr. Nadav Friedmann M.D., Ph.D. Chief Medical Officer & Director 1943
Dr. James W. Kupiec M.D. Chief Clinical Devel. Officer NA
Dr. George Thornton Sr. VP of Technology NA
Mr. R. Christopher Cook Sr. VP & Gen. Counsel NA
Mr. Michael Zamloot Sr. VP of Technical Operations NA
Dr. Michael Marsman Pharm.D. Sr. VP of Regulatory Affairs NA
Dr. Lindsay H. Burns Ph.D. Sr. VP of Neuroscience NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).